Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 ...

Passage Bio’s workforce reduction could affect about 32 people, leaving the company with 26 employees as it continues ...

Biogen’s proposed acquisition comes after two difficult years of regulatory and clinical challenges, during which shares of ...

Emraclidine was the centerpiece of AbbVie’s $8.7 billion acquisition of Cerevel in December 2023 but failed two mid-stage ...

Benefiting from technological and conceptual groundwork and positive early data, gene therapies are advancing in the clinic ...

Among the 55 novel drugs that crossed the regulatory finish line last year were notable new mechanisms of action, coming ...

The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.

Cellular’s neuropsychiatric assets is Caplyta, a pill approved for schizophrenia and bipolar depression and proposed for major depressive disorder.

An FDA committee’s September 2024 vote to limit the use of Merck’s Keytruda and BMS’ Opdivo in stomach and esophageal cancers ...

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...

After the successful development of mavacamten and the sale of MyoKardia to BMS in 2020, former executives of the biotech are ...